This NDC is on FDA's drug shortage list (posted Jul 14, 2023)

Reported reason: Shortage of an active ingredient

Product Information

LISDEXAMFETAMINE 30 MG CAPSULE is a generic product labeled by Rhodes Pharmaceuticals L.P., priced at $2.6640 per EA under NDC 42858016301. Its NADAC has been published 122 times since Apr 24, 2024.

FDA first approved this application on Aug 25, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

LISDEXAMFETAMINE 30 MG CAPSULE

LISDEXAMFETAMINE DIMESYLATE
$2.6640per EA
DEA Schedule CII

Strength

30 mg/1

NDC

42858016301

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

LISDEXAMFETAMINE DIMESYLATE

Approval Type

Generic (ANDA)

FDA Application

ANDA215330

FDA Approved

8/25/2023

TE Code

AB

On Market Since

1/30/2024

Pharmacological Classes

Central Nervous System Stimulant
Central Nervous System Stimulation

Price Statistics

The NADAC for LISDEXAMFETAMINE 30 MG CAPSULE has been published 122 times since Apr 24, 2024, and over the history we have for it it has declined 58.2%. The table below summarizes its recorded NADAC range and movement.

Current price$2.6640 per EA
All-time high$6.3697 (May 15, 2024)
All-time low$2.6640 (Aug 19, 2026)
52-week high$3.6233
52-week low$2.6640
Median price$3.6797
Average price$3.9719
Largest weekly change+59.1% (Jun 19, 2024)
Weeks tracked122
Tracking sinceApr 24, 2024

Price History

1W

-3.7%

1M

-3.7%

3M

-14.7%

6M

-10.6%

1Y

-26.5%

3Y

N/A

5Y

N/A

All

-58.2%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of LISDEXAMFETAMINE 30 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for LISDEXAMFETAMINE 30 MG CAPSULE, manufactured by Rhodes Pharmaceuticals L.P., is $2.6640 per EA (NDC 42858016301), effective Aug 19, 2026.

How has the price of LISDEXAMFETAMINE 30 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for LISDEXAMFETAMINE 30 MG CAPSULE has declined 58.2%. It has been tracked across 122 weekly CMS publications since Apr 24, 2024.

What are the highest and lowest recorded NADAC prices for LISDEXAMFETAMINE 30 MG CAPSULE?

Since Apr 24, 2024, the NADAC for LISDEXAMFETAMINE 30 MG CAPSULE has ranged from a low of $2.6640 (Aug 19, 2026) to a high of $6.3697 (May 15, 2024), with a median of $3.6797 per EA.

Are there cheaper alternatives to LISDEXAMFETAMINE 30 MG CAPSULE?

2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LISDEXAMFETAMINE 30 MG CAPSULE in a comparable dosage form, but none are currently priced below it.

Who manufactures LISDEXAMFETAMINE 30 MG CAPSULE?

LISDEXAMFETAMINE 30 MG CAPSULE (NDC 42858016301) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a generic product.

Is LISDEXAMFETAMINE 30 MG CAPSULE in shortage?

Yes — NDC 42858016301 is currently listed in FDA's drug shortage database (posted Jul 14, 2023). Reported reason: Shortage of an active ingredient.